- Home
- RCS vs HELP Comparison
RCS vs HELP Comparison
Compare RCS & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | HELP |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.0M | 233.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCS | HELP |
|---|---|---|
| Price | $5.16 | $7.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 118.5K | ★ 2.0M |
| Earning Date | 01-01-0001 | 07-01-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.09 | $3.76 |
| 52 Week High | $8.00 | $8.55 |
Technical Indicators
Market Signals| Indicator | RCS | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 34.45 | 62.04 |
| Support Level | $5.09 | $4.18 |
| Resistance Level | $5.67 | $8.55 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 5.00 | 59.70 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.